A detailed history of Teacher Retirement System Of Texas transactions in Arvinas, Inc. stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 10,533 shares of ARVN stock, worth $285,549. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,533
Previous 12,864 18.12%
Holding current value
$285,549
Previous $531,000 47.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$24.46 - $40.4 $57,016 - $94,172
-2,331 Reduced 18.12%
10,533 $280,000
Q1 2024

May 06, 2024

BUY
$36.38 - $52.31 $85,274 - $122,614
2,344 Added 22.28%
12,864 $531,000
Q4 2023

Feb 07, 2024

SELL
$14.19 - $42.33 $33,587 - $100,195
-2,367 Reduced 18.37%
10,520 $433,000
Q3 2023

Oct 31, 2023

BUY
$19.64 - $28.21 $11,823 - $16,982
602 Added 4.9%
12,887 $253,000
Q2 2023

Jul 19, 2023

SELL
$21.73 - $31.43 $35,919 - $51,953
-1,653 Reduced 11.86%
12,285 $305,000
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $364,478 - $519,329
13,938 New
13,938 $381,000
Q3 2022

Nov 03, 2022

SELL
$41.87 - $57.99 $20,767 - $28,763
-496 Reduced 7.04%
6,553 $292,000
Q2 2022

Aug 09, 2022

SELL
$36.01 - $74.24 $39,935 - $82,332
-1,109 Reduced 13.59%
7,049 $297,000
Q1 2022

May 09, 2022

BUY
$60.27 - $81.57 $62,078 - $84,017
1,030 Added 14.45%
8,158 $549,000
Q4 2021

Feb 10, 2022

BUY
$65.85 - $96.21 $91,004 - $132,962
1,382 Added 24.05%
7,128 $585,000
Q3 2021

Nov 09, 2021

BUY
$73.2 - $107.87 $135,493 - $199,667
1,851 Added 47.52%
5,746 $472,000
Q2 2021

Aug 05, 2021

BUY
$60.45 - $84.26 $36,511 - $50,893
604 Added 18.35%
3,895 $300,000
Q1 2021

May 11, 2021

BUY
$58.19 - $91.37 $191,503 - $300,698
3,291 New
3,291 $218,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.44B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.